Nelson H
Department of Surgery, Mayo Foundation, Rochester, Minnesota 55905.
Cancer Cells. 1991 May;3(5):163-72.
Linking an antitumor cell antibody with an antilymphocyte antibody produces a bifunctional antibody that can redirect T lymphocytes to lyse tumor cells. Bifunctional antibodies that bypass the normal specificity of the T cell antigen receptor can, theoretically, retarget all of a cancer patient's cytotoxic T lymphocytes to kill tumor cells. Studies have demonstrated that bifunctional antibodies redirect effector cells to lyse human tumor cells in vitro and neutralize human tumor xenografts in animal models. Several different effector cell populations have been studied and many different human tumors have been targeted for lysis. Current research goals include the improvement of methods for the preparation of antibody reagents and the enhancement of cellular trafficking to tumors.
将抗肿瘤细胞抗体与抗淋巴细胞抗体连接可产生双功能抗体，该抗体能够使T淋巴细胞重新定向以裂解肿瘤细胞。理论上，绕过T细胞抗原受体正常特异性的双功能抗体可以将癌症患者所有的细胞毒性T淋巴细胞重新定向，以杀死肿瘤细胞。研究表明，双功能抗体可在体外使效应细胞重新定向以裂解人类肿瘤细胞，并在动物模型中中和人类肿瘤异种移植物。已经研究了几种不同的效应细胞群体，并且针对裂解作用靶向了许多不同的人类肿瘤。当前的研究目标包括改进抗体试剂的制备方法以及增强细胞向肿瘤的转运。
